Please login to the form below

Pricing and Market Access Simulator

Reliable tool for value assessment of pipeline products

YOUR CHALLENGE:
PRICING A PRODUCT EARLY IN DEVELOPMENT

Predicting pricing scenarios for products early in development is a critical go/no-go step for companies looking to deliver innovative compounds that payers and providers will take up. The challenge for business development and licensing professionals is to fi nd promising targets, and understand where to invest in the development of the product to be able to gain the optimal price and access outcome.

OUR SOLUTION:
VALID INSIGHT’S PRICING AND MARKET ACCESS SIMULATOR

Valid Insight’s pricing and market access simulator app can evaluate your product’s pricing and funding potential rapidly and effectively, and determine the focus of product development to bring optimal value at launch.

The pricing and market access simulator app offers you a unique opportunity to take early investment decisions more robustly than ever:

 Prioritise indications based on relative value across disease areas

 Plan product development strategies that will lead to optimal pricing

 Align evidence generation and product development strategies between medical, market access, HEOR, commercial and product development teams

 Optimise product positioning to create a differentiated value proposition.

VALIDATION OF THE TOOL
The tool is based on multi-criteria decision analysis of over 10 years of decisions on reimbursement and pricing for new pharmaceutical products in Belgium, Bulgaria, Catalonia, England and Wales, France, Germany, Italy, Netherlands, Poland, Portugal, Scotland, Spain, Sweden, and US.

HOW DOES IT WORK?
Valid Insight’s pricing and market access simulator app uses proprietary algorithms backed up by analysis of over a decade of decisions on reimbursement and pricing for new pharmaceuticals covering the major market archetypes across Europe and the US. Input your criteria through a guided step-by-step process in our simple and easy to use interface. By running different scenarios and adjusting different factors each time, the app will help you to find the optimal strategy for different markets. The app enables strategic mapping of your products and those of your competitors on an interactive visual scale based on clinical value and willingness to pay. Importantly, the tool identifies the elements that have the most positive impact and those which require further development consideration. Valid Insight’s pricing and market access simulator app can predict pricing and reimbursement outcomes at any stage before a product is launched. However, it is most useful for predictions pre-phase III. Once a product gets closer to launch Valid Insight recommends using stakeholder research for robust price setting.

Call us on +44(0)203 750 9833 or drop an email to the Valid Insight team at discover@validinsight.com

10th February 2020

Share

Tags

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

Valid Insight are hiring for Consultants in Value Communication (mid to senior levels)
New role available for Consultants in Value Communication with experience in market access writing and value communication.
Valid Insight
Webinar: Maintaining market access through a pandemic, 6 months on
In this webinar, Valid Insight explore market access and how it has evolved through a pandemic over the past 6 months.
Valid Insight
Webinar: How to develop an optimal value story for your product
This webinar is part of the ongoing expert insights series run by Valid Insight
Valid Insight
Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight